UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Combination therapy for chronic hepatitis B virus infection

Author
Anna SF Lok, MD
Section Editor
Rafael Esteban, MD
Deputy Editor
Jennifer Mitty, MD, MPH

INTRODUCTION

Monotherapy with a single antiviral agent or interferon is unlikely to be sufficient for the eradication of hepatitis B virus (HBV) infection in the majority of patients who are chronically infected. With the availability of several medications, it is now possible to contemplate combination therapy for hepatitis B [1]. Such an approach has proven to be beneficial in patients with HIV infection and those with chronic hepatitis C. (See "Selecting antiretroviral regimens for the treatment-naïve HIV-infected patient" and "Overview of the management of chronic hepatitis C virus infection".)

Ideally, therapeutic agents used in combination therapy should have additive or synergistic activity against HBV, delay or prevent the development of drug resistance, have no added toxicity, and promote restoration of immune response to HBV. The question is which agents to combine: two nucleos(t)ide analogs or one nucleos(t)ide analog plus interferon?

This topic review will summarize experience with combination therapy for chronic hepatitis B virus infection. Early experience involves the addition of another agent to lamivudine (see "Lamivudine monotherapy for chronic hepatitis B virus infection"). None of the combination approaches has been approved for routine use.

STANDARD INTERFERON PLUS LAMIVUDINE

The combination of lamivudine and interferon seems logical because monotherapy with each agent is effective, and lamivudine and interferon have different mechanisms of action. However, disparate results have been described in controlled trials.

Treatment-naïve patients — There are conflicting data on the outcome after combination therapy in treatment-naïve patients [2-4]. One trial included 230 patients from Europe, Canada, and Australia who were randomly assigned to one of three treatment arms [2]:

                  

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2016. | This topic last updated: Mon Nov 28 00:00:00 GMT+00:00 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
References
Top
  1. Richman DD. The impact of drug resistance on the effectiveness of chemotherapy for chronic hepatitis B. Hepatology 2000; 32:866.
  2. Schalm SW, Heathcote J, Cianciara J, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 2000; 46:562.
  3. Barbaro G, Zechini F, Pellicelli AM, et al. Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter, randomized trial. J Hepatol 2001; 35:406.
  4. Santantonio T, Niro GA, Sinisi E, et al. Lamivudine/interferon combination therapy in anti-HBe positive chronic hepatitis B patients: a controlled pilot study. J Hepatol 2002; 36:799.
  5. Schiff ER, Dienstag JL, Karayalcin S, et al. Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders. J Hepatol 2003; 38:818.
  6. Tatulli I, Francavilla R, Rizzo GL, et al. Lamivudine and alpha-interferon in combination long term for precore mutant chronic hepatitis B. J Hepatol 2001; 35:805.
  7. Janssen HL, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005; 365:123.
  8. Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351:1206.
  9. Chan HL, Leung NW, Hui AY, et al. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone. Ann Intern Med 2005; 142:240.
  10. Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352:2682.
  11. Chan HL, Hui AY, Wong VW, et al. Long-term follow-up of peginterferon and lamivudine combination treatment in HBeAg-positive chronic hepatitis B. Hepatology 2005; 41:1357.
  12. Piratvisuth T, Luo KX, Marcellin P, et al. Effect of ALT flares on efficacy and safety of peginterferon alfa-2a, peginterferon alfa-2a plus lamivudine and lamivudine in HBeAg-positive chronic hepatitis B (abstract). J Hepatol 2005; :(Suppl).
  13. Flink HJ, Sprengers D, Hansen BE, et al. Flares in chronic hepatitis B patients induced by the host or the virus? Relation to treatment response during Peg-interferon {alpha}-2b therapy. Gut 2005; 54:1604.
  14. Marcellin P, Bonino F, Lau GK, et al. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. Gastroenterology 2009; 136:2169.
  15. Lampertico P, Viganò M, Di Costanzo GG, et al. Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B. Gut 2013; 62:290.
  16. Xie Q, Zhou H, Bai X, et al. A randomized, open-label clinical study of combined pegylated interferon Alfa-2a (40KD) and entecavir treatment for hepatitis B "e" antigen-positive chronic hepatitis B. Clin Infect Dis 2014; 59:1714.
  17. Brouwer WP, Xie Q, Sonneveld MJ, et al. Adding pegylated interferon to entecavir for hepatitis B e antigen-positive chronic hepatitis B: A multicenter randomized trial (ARES study). Hepatology 2015; 61:1512.
  18. Marcellin P, Ahn SH, Ma X, et al. Combination of Tenofovir Disoproxil Fumarate and Peginterferon α-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B. Gastroenterology 2016; 150:134.
  19. Wursthorn K, Lutgehetmann M, Dandri M, et al. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology 2006; 44:675.
  20. Lutgehetmann M, Volzt T, Quaas A, et al. Sequential combination therapy leads to biochemical and histological improvement despite low ongoing intrahepatic hepatitis B virus replication. Antivir Ther 2008; 13:57.
  21. Marcellin P, Wursthorn K, Wedemeyer H, et al. Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B is associated with an unexpected high rate of peripheral neuropathy. J Hepatol 2015; 62:41.
  22. Lok AS, Trinh H, Carosi G, et al. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B. Gastroenterology 2012; 143:619.
  23. Petersen J, Ratziu V, Buti M, et al. Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: an international multicenter cohort study. J Hepatol 2012; 56:520.